Midodrine plus propranolol versus propranolol alone in preventing first bleed in patients with cirrhosis and severe ascites: a randomized controlled trial Abhijeet RanjanAnkur JindalShiv K. Sarin Original Article 10 May 2024
Is the TAE score a promising prognostic predictor for unresectable hepatocellular carcinoma treated with TACE plus lenvatinib with PD‑1 inhibitors? Further validation should be performed Shiye YangHuoqi LiangZhibing Ming Letter to the Editor 08 May 2024
Gut-microbiome composition and function in progression of alcohol-associated liver disease: going beyond western experiences Gowthami KanagalingamJasmohan S. Bajaj Editorial 08 May 2024
MAFLD identifies patients with significant hepatic fibrosis better than MASLD Ziyan PanSaid A. Al-BusafiMohammed Eslam Original Article 08 May 2024
Hepatic artery infusion chemotherapy combined with camrelizumab plus rivoceranib for hepatocellular carcinoma with portal vein tumor thrombosis: a multicenter propensity score-matching analysis Yangyang LiJiandong GuoChengzhi Li Original Article Open access 08 May 2024
Lifestyle intervention for metabolic dysfunction-associated fatty liver disease: a 24-h integrated behavior perspective Shelley E. KeatingYogesh ChawlaElena S. George Special supplement : MAFLD Open access 08 May 2024
Incidence, risk factors, and outcomes of acute liver injury in hospitalized adults with acute kidney injury: a large multicenter study Yuxin LinPingping Lifor the CRDS Study Investigators Original Article 02 May 2024
Regarding the role of post-transplant inflammatory cytokine signature on predicting tumor recurrence after liver transplantation for hepatocellular carcinoma Bing ChenBojie Huang Letter to the Editor 29 April 2024
Clinical evaluation of droplet digital pcr for suspected ascites infection in patients with liver cirrhosis Jie HanFei-li WeiZhong-jie Hu Original Article 29 April 2024
The contribution of genetics and epigenetics to MAFLD susceptibility Vittoria MorettiStefano RomeoLuca Valenti Special supplement: MAFLD Open access 25 April 2024
Predicting response to non-selective beta-blockers with liver–spleen stiffness and heart rate in patients with liver cirrhosis and high-risk varices Mauro GiuffrèJohannes DupontThe NSBB-Elasto-Response-Prediction Group Original Article Open access 25 April 2024
PIVKA-II combined with alpha-fetoprotein for the diagnostic value of hepatic tumors in children: a multicenter, prospective observational study Hongxiang GaoChenjie XieSong Gu Original Article Open access 16 April 2024
MAFLD as part of systemic metabolic dysregulation Jing ZhaoLu LiuMing-Hua Zheng Special supplement : MAFLD 09 April 2024
Efficacy and safety of precision-guided transjugular extrahepatic portosystemic shunt (TEPS) in the management of cavernous transformation of the portal vein with portal hypertension: a case series Liu ZhangYi-Jiang ZhuChun-Ze Zhou Original Article Open access 09 April 2024
APASL clinical practice guidelines on the management of acute kidney injury in acute-on-chronic liver failure Rakhi MaiwallSatender Pal SinghShiv Kumar Sarin Guidelines 05 April 2024
Liver fibrosis showed a two-phase regression rate during long-term anti-HBV therapy by three-time biopsies assessments Shuyan ChenJialing ZhouHong You Original Article 02 April 2024
Evaluation of the histologic and immunohistochemical (CD34, glutamine synthetase) findings in idiopathic non-cirrhotic portal hypertension (INCPH) Melek BüyükNeslihan BerkerMine Güllüoğlu Original Article Open access 27 March 2024
Global burden and trends of acute viral hepatitis among children and adolescents from 1990 to 2019: a systematic analysis of the Global Burden of Disease Study 2019 Wanglong XiaoJingwei ZhaoQiang Xia Original Article 26 March 2024
Prophylaxis of hepatic encephalopathy: current and future drug targets Sudhir MaharshiBarjesh Chander Sharma Review Article 16 March 2024
Safety of right liver donation after improving steatosis through weight loss in living donors: a retrospective study Young-In YoonSung-Gyu LeeGil-Chun Park Original Article 15 March 2024
Laparoscopic liver resection is superior to radiofrequency ablation for small hepatocellular carcinoma: a systematic review and meta-analysis of propensity score-matched studies Wen ChenXiaodan LinYanling Chen Original Article 14 March 2024
“Dosis sola facit venenum”—Evidence for causality in the association between ketamine and cholestatic liver injury Pedro David Wendel-GarciaRea AndermattKlaus Stahl Letter to the Editor Open access 13 March 2024
Surgical risk stratification in patients with cirrhosis Ana OstojicNadim MahmudK. Rajender Reddy Review Article 12 March 2024
Predictors of HBsAg seroclearance in patients with chronic HBV infection treated with pegylated interferon-α: a systematic review and meta-analysis Shaowen JiangSimin GuoQing Xie Original Article Open access 09 March 2024
Expert consensus on the diagnosis and treatment of end-stage liver disease complicated by infections Tao ChenGuang ChenQin Ning Guidelines 09 March 2024
Correction to: Complementary role of peripheral and central autonomic nervous system on insulin-like growth factor-1 activation to prevent fatty liver disease Itsuo NagayamaKenya KamimuraShuji Terai Correction 07 March 2024
Are dairy products the answer to metabolic dysfunction-associated fatty liver disease? Kristopher Cho-Hei LauVincent Wai-Sun Wong Editorial 07 March 2024
Impact of chronic hepatitis B and concurrent steatosis on the risk of hepatocellular carcinoma Ibrahim AyadaJiajing LiQiuwei Pan Letter to the Editor 07 March 2024
Comments on: Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis Yan WangXiu SunQi Mei Letter to the Editor Open access 02 March 2024 Pages: 702 - 703
Pre-hepatectomy dynamic circulating tumor DNA to predict pathologic response to preoperative chemotherapy and post-hepatectomy recurrence in patients with colorectal liver metastases Ming LiuQuan BaoBaocai Xing Original Article 01 March 2024
Response to letter to editor for risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis Jin Wook ParkJeong-Ju YooYoung Seok Kim Letter to the Editor 29 February 2024 Pages: 700 - 701
Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantation Dong-Sik KimYoung-In Yoonfor Asian Pacific Association for Study of Liver (APASL) Guidelines 28 February 2024 Pages: 299 - 383
Dairy products intake and prevalence, incidence, and recovery of non-alcoholic fatty liver disease in Chinese population Yurou XuYouyi WangXing Liu Original Article 26 February 2024 Pages: 529 - 539
Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update Yimin MaoShiwu Mathe Technology Committee on DILI Prevention, Management, Chinese Medical Biotechnology Association; Study Group on Drug-Induced Liver Disease, Chinese Society of Hepatology, Chinese Medical Association Guidelines 24 February 2024 Pages: 384 - 419
Preventing viral relapse with prophylactic tenofovir in hepatitis B carriers receiving chemotherapy: a phase IV randomized study in Taiwan Chao-Wei HsuShin-Cheh ChenChau-Ting Yeh Original Article 20 February 2024 Pages: 449 - 460
Functional cure is associated with younger age in children undergoing antiviral treatment for active chronic hepatitis B Min ZhangJing LiFu-Sheng Wang Original Article Open access 20 February 2024 Pages: 435 - 448
Artificial intelligence in liver imaging: methods and applications Peng ZhangChaofei GaoXiaolong Qi Review Article 20 February 2024 Pages: 422 - 434
Prevalence and impact on the outcome of myosteatosis in patients with cirrhosis: a systematic review and meta-analysis Aikaterini KamiliouVasileios LekakisEvangelos Cholongitas Original Article Open access 08 February 2024 Pages: 688 - 699
Is TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors superior to TACE plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: the debate continues Shiye YangHuoqi LiangZhibing Ming Letter to the Editor 08 February 2024
FXR-FGF19 signaling in the gut–liver axis is dysregulated in patients with cirrhosis and correlates with impaired intestinal defence Benedikt SimbrunnerBenedikt S. HoferThomas Reiberger Original Article Open access 08 February 2024
Correction to: Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines Wei TengTing‑Tsung ChangJaw‑Ching Wu Correction 22 January 2024
The impact of an increased Fibrosis-4 index and the severity of hepatic steatosis on mortality in individuals living with diabetes Xiaoyan MaYixuan ZhuJie Li Original Article 22 January 2024
An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan Ming-Lung YuChi‐Ming TaiCheng-Yuan Peng Original Article Open access 21 January 2024 Pages: 461 - 475
Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease Shao-Wen WangTsung-Han HsiehJia-Horng Kao Original Article 16 January 2024
Organ-specific response with first-line atezolizumab-bevacizumab versus lenvatinib for patients with advanced hepatocellular carcinoma Hyung-Don KimYoung-Gyu ParkChanghoon Yoo Original Article 12 January 2024
FXR overexpression prevents hepatic steatosis through inhibiting AIM2 inflammasome activation in alcoholic liver disease Lin LiLina KongQiang Meng Original Article 06 January 2024 Pages: 188 - 205
The upregulation of Annexin A2 by TLR4 pathway facilitates lipid accumulation and liver injury via blocking AMPK/mTOR-mediated autophagy flux during the development of non-alcoholic fatty liver disease Haifeng WuMeng ZhouJinxia Liu Original Article 06 January 2024
